Show simple item record

dc.contributor.authorLuo, Y
dc.contributor.authorPaul, SK
dc.contributor.authorZhou, X
dc.contributor.authorChang, C
dc.contributor.authorChen, W
dc.contributor.authorGuo, X
dc.contributor.authorYang, J
dc.contributor.authorJi, L
dc.contributor.authorWang, H
dc.date.accessioned2020-12-21T04:19:36Z
dc.date.available2020-12-21T04:19:36Z
dc.date.issued2017-01-01
dc.identifier.citationLuo, Y., Paul, S. K., Zhou, X., Chang, C., Chen, W., Guo, X., Yang, J., Ji, L. & Wang, H. (2017). Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes. JOURNAL OF DIABETES RESEARCH, 2017, https://doi.org/10.1155/2017/7602408.
dc.identifier.issn2314-6745
dc.identifier.urihttp://hdl.handle.net/11343/257575
dc.description.abstractBackground. Patients with prediabetes are at high risk for diabetes and cardiovascular disease (CVD). No study has explored whether intervention could revert prediabetes to normal glycemic status as the primary outcome. Beijing Prediabetes Reversion Program (BPRP) would evaluate whether intensive lifestyle modification and/or pioglitazone could revert prediabetic state to normoglycemia and improve the risk factors of CVD as well. Methods. BPRP is a randomized, multicenter, 2 × 2 factorial design study. Participants diagnosed as prediabetes were randomized into four groups (conventional/intensive lifestyle intervention and 30 mg pioglitazone/placebo) with a three-year follow-up. The primary endpoint was conversion into normal glucose tolerance. The trial would recruit 2000 participants (500 in each arm). Results. Between March 2007 and March 2011, 1945 participants were randomized. At baseline, the individuals were 53 ± 10 years old, with median BMI 26.0 (23.9, 28.2) kg/m2 and HbA1c 5.8 (5.6, 6.1)%. 85% of the participants had IGT and 15% had IFG. Parameters relevant to glucose, lipids, blood pressure, lifestyle, and other metabolic markers were similar between conventional and intensive lifestyle intervention group at baseline. Conclusion. BPRP was the first study to determine if lifestyle modification and/or pioglitazone could revert prediabetic state to normoglycemia in Chinese population. Major baseline parameters were balanced between two lifestyle intervention groups. This trial is registered with www.chictr.org.cn: ChiCTR-PRC-06000005.
dc.languageEnglish
dc.publisherHINDAWI LTD
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleRationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes
dc.typeJournal Article
dc.identifier.doi10.1155/2017/7602408
melbourne.affiliation.departmentMedicine (RMH)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleJournal of Diabetes Research
melbourne.source.volume2017
dc.rights.licenseCC BY
melbourne.elementsid1183646
melbourne.contributor.authorPaul, Sanjoy
dc.identifier.eissn2314-6753
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record